BACKGROUND: The CAPTIM trial suggested a survival benefit of prehospital fibrinolysis (FL) compared to primary percutaneous coronary intervention (PCI) in patients with ST-elevation myocardial infarction (STEMI) with a presentation delay of <2 hours. We examined the relationship between reperfusion strategy and time from symptom onset on 1-year mortality in a combined analysis of 1,168 patients with STEMI. METHODS:Individual patient data from CAPTIM (n = 840, 1997-2000) and the more recent WEST trial (n = 328, 2003-2005) were pooled. RESULTS:Median age was 58 years, 81% were men, and 41% had anterior myocardial infarction; 640 patients were randomized to FL versus 528 patients to PCI. Both arms received contemporary adjunctive medical therapy. Presentation delay (ie, symptom onset to randomization) was similar in FL and PCI patients (median 105 [72-158] vs 106 [74-162] minutes, P = .712). Rescue PCI after FL occurred in 26% and 27%, and 30-day PCI, in 70% and 71% in CAPTIM and WEST, respectively. Mortality was not different between FL and PCI (4.6% vs 6.5%, P = .263); however, the interaction between presentation delay and treatment was significant (P = .043). Benefit with FL was observed with time <2 hours (2.8% [FL] vs 6.9% [PCI], P = .021, hazard ratio [HR] 0.43, 95% CI 0.20-0.91), whereas beyond 2 hours, no treatment difference was observed (6.9% [FL] vs 6.0% [PCI], P = .529, HR 1.23, 95% CI 0.61-2.46). CONCLUSIONS: A strategy of early FL demonstrated a reduction in 1-year mortality compared to primary PCI in early presenters. Time from symptom onset should be a key consideration when selecting reperfusion therapy for STEMI.
RCT Entities:
BACKGROUND: The CAPTIM trial suggested a survival benefit of prehospital fibrinolysis (FL) compared to primary percutaneous coronary intervention (PCI) in patients with ST-elevation myocardial infarction (STEMI) with a presentation delay of <2 hours. We examined the relationship between reperfusion strategy and time from symptom onset on 1-year mortality in a combined analysis of 1,168 patients with STEMI. METHODS: Individual patient data from CAPTIM (n = 840, 1997-2000) and the more recent WEST trial (n = 328, 2003-2005) were pooled. RESULTS: Median age was 58 years, 81% were men, and 41% had anterior myocardial infarction; 640 patients were randomized to FL versus 528 patients to PCI. Both arms received contemporary adjunctive medical therapy. Presentation delay (ie, symptom onset to randomization) was similar in FL and PCI patients (median 105 [72-158] vs 106 [74-162] minutes, P = .712). Rescue PCI after FL occurred in 26% and 27%, and 30-day PCI, in 70% and 71% in CAPTIM and WEST, respectively. Mortality was not different between FL and PCI (4.6% vs 6.5%, P = .263); however, the interaction between presentation delay and treatment was significant (P = .043). Benefit with FL was observed with time <2 hours (2.8% [FL] vs 6.9% [PCI], P = .021, hazard ratio [HR] 0.43, 95% CI 0.20-0.91), whereas beyond 2 hours, no treatment difference was observed (6.9% [FL] vs 6.0% [PCI], P = .529, HR 1.23, 95% CI 0.61-2.46). CONCLUSIONS: A strategy of early FL demonstrated a reduction in 1-year mortality compared to primary PCI in early presenters. Time from symptom onset should be a key consideration when selecting reperfusion therapy for STEMI.
Authors: Bernhard Jäger; Serdar Farhan; Karim Kalla; Helmut D Glogar; Günter Christ; Ronald Karnik; Georg Norman; Herbert Prachar; Wolfgang Schreiber; Alfred Kaff; Andrea Podczeck-Schweighofer; Franz Weidinger; Thomas Stefenelli; Georg Delle-Karth; Anton N Laggner; Gerald Maurer; Kurt Huber Journal: Wien Klin Wochenschr Date: 2015-07-11 Impact factor: 1.704
Authors: Juho Viikilä; Jyrki Lilleberg; Ilkka Tierala; Mikko Syvänne; Markku Kupari; Veikko Salomaa; Markku S Nieminen Journal: Eur Heart J Acute Cardiovasc Care Date: 2013-08-21
Authors: Manuel Chacón-Diaz; Piero Custodio-Sánchez; Paol Rojas De la Cuba; Germán Yábar-Galindo; René Rodríguez-Olivares; David Miranda-Noé; Luis Marcos López-Rojas; Akram Hernández-Vásquez Journal: BMC Cardiovasc Disord Date: 2022-06-29 Impact factor: 2.174
Authors: Mikkel M Schoos; Maria Sejersten; Anders Hvelplund; Mette Madsen; Jacob Lønborg; Jacob Steinmetz; Philip M Treschow; Frants Pedersen; Erik Jørgensen; Peer Grande; Henning Kelbæk; Peter Clemmensen Journal: Eur Heart J Acute Cardiovasc Care Date: 2012-09
Authors: Jay Shavadia; Yinggan Zheng; Neda Dianati Maleki; Kurt Huber; Sigrun Halvorsen; Patrick Goldstein; Anthony H Gershlick; Robert Wilcox; Frans Van de Werf; Paul W Armstrong Journal: J Am Heart Assoc Date: 2015-08-24 Impact factor: 5.501